Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients

•Observation of the clinical efficacy in three real-world DAAs cohorts in China.•Previous studies focused on changes of HCV genomes under selective pressure in relapsed patients are limited.•Next-generation sequencing was used as the detection method to cover near full-length genome of HCV (27 gene...

Full description

Saved in:
Bibliographic Details
Published in:Virus research 2021-09, Vol.302, p.198453-198453, Article 198453
Main Authors: Deng, Haohui, Guo, Fengxia, Yu, Weihua, Li, Linghua, Xia, Yang, Guan, Yujuan, Li, Jianping
Format: Article
Language:English
Subjects:
Antiviral Agents - pharmacology
clinical efficacy
direct-acting antiviral drugs
Drug Resistance, Viral - genetics
Genotype
Hepacivirus - genetics
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Humans
next-generation sequencing
Recurrence
sequence analysis
Viral Nonstructural Proteins - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Observation of the clinical efficacy in three real-world DAAs cohorts in China.•Previous studies focused on changes of HCV genomes under selective pressure in relapsed patients are limited.•Next-generation sequencing was used as the detection method to cover near full-length genome of HCV (27 gene fragments for 1b and 3b, 26 gene fragments for 6a).•Resistance-associated variants, viral quasispecies diversity and selection analysis were analyzed in this study. Currently, direct-acting antiviral drugs (DAAs) are widely used as therapeutic methods for hepatitis C virus (HCV)-positive patients, however, patients may experience treatment failure, and the dynamic changes of HCV genomes in these patients are unknown. In this study, three real-world DAAs cohorts were enrolled to observe clinical efficacy. In addition, serum samples from treatment failure patients at baseline and relapse were used to analyze changes of the HCV genomes at near full-length genome level, including resistance-associated variants (RAVs), viral quasispecies diversity and selection analysis. Next-generation sequencing was used as the detection method. The overall sustained virological response at 12 w after the end of treatment was achieved in 91.9% (57/62) of HCV patients, and 3 paired samples obtained from relapsed patients. All the 3 patients harbored baseline NS5A RAVs, the frequency of NS5A RAVs increased in 2 patients and a new NS5A RAV emerged in 1 patient at relapse, and almost all the viral strains existed with NS5A RAVs at relapse. The results of the viral quasispecies diversity analysis revealed that viral quasispecies diversity decreased at relapse compared to baseline, and the results of selection analysis indicated that the virus population experienced a bottleneck phenomenon, recent selective sweep and population expansion or was under purification selection after DAAs treatment. This study indicated that the clinical efficacy was excellent in real-world DAAs cohorts, and the viral strains existed at relapse were selective by DAAs therapy.
ISSN:0168-1702
1872-7492
DOI:10.1016/j.virusres.2021.198453